定量磁化率图用于成人型弥漫性胶质瘤的综合评估
回顾性分析70例病理确诊的成人型弥漫性胶质瘤患者,基于2021年WHO中枢神经系统肿瘤分类,评估QSM上的瘤内磁敏感信号(ITSS)及区域磁敏感值对胶质瘤分级、分子分型、预后和复发的预测价值。结果显示ITSS分级与WHO分级、IDH状态、1年生存和复发显著相关,高磁敏感区的磁敏感值与WHO分级、IDH状态、MGMT启动子甲基化和Ki67指数显著相关,ITSS 0级患者总生存期显著优于1-3级,且为独立预后因素。作者认为这些初步发现提示QSM可能作为无创影像生物标志物用于成人型弥漫性胶质瘤的综合评估。
要点
- ITSS分级与胶质瘤WHO分级、IDH状态、1年生存及复发显著相关。
- 肿瘤内相对高磁敏感区的磁敏感值与WHO分级、IDH状态、MGMT启动子甲基化和Ki67指数显著相关。
- ITSS 0级患者总生存期显著优于1-3级,且为独立预后因素。
核心结论
- 从QSM图像提取的无创影像参数可反映胶质瘤WHO分级、分子标志物、预后和复发风险,这些初步发现提示QSM可能作为成人型弥漫性胶质瘤综合评估的无创影像生物标志物。
研究设计与样本
- 回顾性分析70例病理确诊的成人型弥漫性胶质瘤患者,基于2021年WHO中枢神经系统肿瘤分类,在QSM上评估ITSS数量并在肿瘤内相对高磁敏感区和相对低磁敏感区测量磁敏感值,分析其与WHO分级、IDH状态、MGMT启动子甲基化、TERT突变、Ki67表达、预后和复发的关系。
关键影像表现/征象
- ITSS分级与胶质瘤WHO分级显著相关(p < 0.001)。
- ITSS分级与IDH状态显著相关(p < 0.001)。
- ITSS分级与1年生存显著相关(p = 0.049)。
- ITSS分级与复发显著相关(p = 0.005)。
- 肿瘤内相对高磁敏感区的磁敏感值与WHO分级(p < 0.001)、IDH状态(p < 0.001)、MGMT启动子甲基化(p = 0.034)和Ki67标记指数(p = 0.025)显著相关。
诊断标准与关键数值
- ITSS分级与胶质瘤WHO分级显著相关(p < 0.001)。
- 肿瘤内相对高磁敏感区的磁敏感值与胶质瘤WHO分级显著相关(p < 0.001)。
- 肿瘤内相对高磁敏感区的磁敏感值与IDH状态显著相关(p < 0.001)。
- 肿瘤内相对高磁敏感区的磁敏感值与MGMT启动子甲基化显著相关(p = 0.034)。
- 肿瘤内相对高磁敏感区的磁敏感值与Ki67标记指数显著相关(p = 0.025)。
临床应用与阅片要点
- ITSS 0级患者总生存期显著优于ITSS 1-3级患者(p = 0.01),多因素分析显示ITSS分级为独立预后因素(p = 0.042)。
- 肿瘤内相对低磁敏感区的磁敏感值在评估胶质瘤WHO分级、分子标志物、预后和复发方面价值有限。
局限性
- 原文结论称这些为初步发现(preliminary findings)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To comprehensively evaluate the value of intratumoral susceptibility signals (ITSS) and regional susceptibility values on quantitative susceptibility mapping (QSM) for adult-type diffuse glioma grading, molecular typing, prognosis, and recurrence prediction based on the 2021 World Health Organization classification of central nervous system tumors (WHO CNS).
METHODS: A total of 70 pathologically confirmed adult-type diffuse glioma patients were retrospectively analyzed. The number of ITSS was evaluated on QSM, and susceptibility measurements were performed in regions of relatively high susceptibility, and relatively low susceptibility within the tumor. The associations of ITSS and regional susceptibility values with glioma WHO grade, isocitrate dehydrogenase (IDH) status, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, telomerase reverse transcriptase (TERT) mutation, Ki67 expression, prognosis, and recurrence were evaluated.
RESULTS: ITSS grading was significantly associated with glioma WHO grade, IDH status, 1-year survival, and recurrence (p < 0.001, p < 0.001, p = 0.049, p = 0.005, respectively). Relatively high tumor susceptibility was significantly correlated with glioma WHO grade, IDH status, MGMT promoter methylation, and Ki67 labeling index (p < 0.001, p < 0.001, p = 0.034, p = 0.025, respectively). Relatively low tumor susceptibility had limited value in evaluating the WHO grade, molecular markers, prognosis, and recurrence of gliomas. Kaplan-Meier analysis showed significantly better overall survival for ITSS grade 0 compared to grades 1-3 (p = 0.01), and multivariate analysis identified it as an independent prognostic factor (p = 0.042).
CONCLUSIONS: Noninvasive imaging parameters extracted from QSM images can reflect glioma WHO grade, molecular markers, prognosis, and recurrence risk. These preliminary findings showed that the QSM might be a noninvasive imaging biomarker for comprehensive evaluation of adult-type diffuse gliomas.
引用
- Shen P, Li Y, Xu W, et al. Quantitative susceptibility mapping for the comprehensive assessment of adult-type diffuse gliomas. Eur J Radiol. 2025. PMID: 41389558. doi:10.1016/j.ejrad.2025.112595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。